Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Pathology

Pathology & Differential Diagnosis: Decoding Your Report

At a Glance

Pancreatic small cell neuroendocrine carcinoma is diagnosed by combining cell appearance, Ki-67 and mitotic rate, immunostains such as p53 and Rb, and clinical imaging; expert review helps distinguish it from NET G3 or small cell cancer that began in the lung.

Because Pancreatic Small Cell Neuroendocrine Carcinoma (SC-NEC) is both rare and aggressive, the pathology report is the single most important document in your care. It is the roadmap that determines whether you receive intensive chemotherapy or a different approach entirely.

Due to the complexity of these tumors, a second opinion from a pathologist who specializes in neuroendocrine cancers at a high-volume center is strongly advisable, though time-sensitive treatment should not be delayed [1][2].

Key Technical Terms to Know

When you read your report, you will see several terms that describe the “personality” and speed of the cancer:

  • Poorly Differentiated: This means the cancer cells look markedly abnormal or disorganized, lacking the structural patterns typical of normal pancreatic cells [3][4].
  • Small Cell Morphology: This refers to the shape and size of the cells. They are small, round, or oval, often with very little cytoplasm (the fluid inside a cell) and “nuclear molding,” where the cells press against each other like a bag of marbles [5][6].
  • Ki-67 Index: This is a percentage that tells you how many cells are proliferating. In high-grade NEC, this is generally >20%, and in SC-NEC it often exceeds 50% to 80%, though a small biopsy can result in an unreliable estimate [3][7].
  • Mitotic Rate: This is a count of how many cells were caught in the act of dividing under a microscope (mitoses) in a specific area. A high mitotic rate confirms a high-grade, fast-growing tumor [7][8].

The Critical Distinction: NEC vs. NET G3

One of the most common diagnostic pitfalls is confusing Small Cell NEC with a Well-Differentiated Grade 3 Neuroendocrine Tumor (NET G3) [9][10]. While both are “Grade 3” and grow quickly, they are fundamentally different diseases:

Feature Small Cell NEC (Your Diagnosis) Well-Differentiated NET G3
Appearance Poorly differentiated; markedly abnormal, disorganized cells [3] Well-differentiated; cells look more like normal ones [5]
Common Mutations TP53 and RB1 abnormalities [11][12] ATRX, DAXX, or MEN1 [12]
Treatment Aggressive, systemic chemotherapy [13] Highly individualized therapies [1]

Immunohistochemistry (IHC): Supportive Clues

Pathologists use chemical stains called immunohistochemistry (IHC) to identify the tumor’s lineage. No single stain proves the diagnosis; they are part of a broader panel. For SC-NEC, the following patterns are often used:

Confirming Neuroendocrine Origin

  • Synaptophysin, Chromogranin A, and INSM1: These are markers that support neuroendocrine differentiation. Synaptophysin is usually positive in SC-NEC, but Chromogranin A can be weak or negative. INSM1 is a highly reliable marker [8][5][14].

Distinguishing NEC from NET

  • p53 (Abnormal): If p53 shows “strong and diffuse” staining or is completely absent (“null”), it suggests a TP53 mutation, which supports a diagnosis of NEC [12][15].
  • Rb (Loss): The loss of the Retinoblastoma (Rb) protein stain is a hallmark surrogate pattern supporting small cell carcinoma [9][16].
  • ATRX/DAXX (Retained): In SC-NEC, these stains are usually normal (retained). If they are lost, the diagnosis may actually be a well-differentiated NET instead [9][17].

Tests That May Be Considered

A high-quality pathology review for pancreatic SC-NEC integrates multiple factors. When reviewing your report, you might see:

  1. Morphologic Description: Explicit mention of “poorly differentiated” and “small cell” features [8].
  2. Proliferation Data: Both the Ki-67 index (as a percentage) and the mitotic count [18][19].
  3. Specific IHC Results: A tailored panel that might include Synaptophysin, p53, and Rb [5][12].
  4. Site of Origin: Clinical and radiologic correlation is required to definitively rule out a primary lung small cell cancer, as pathology alone cannot [20][21].
  5. Mixed Components: A check for MiNEN (Mixed Neuroendocrine-Non-Neuroendocrine Neoplasm), where traditional pancreatic cancer is mixed with NEC [22][23].
  6. Sampling Caveat: If the diagnosis was made via a small needle biopsy (FNA), the report may note that a small sample might not represent the entire tumor [24].

Common questions in this guide

What does “poorly differentiated small cell” mean in my pathology report?
It means the tumor cells look very unlike normal pancreatic cells and have a small, round or oval shape with little cell fluid. Features such as disorganization and nuclear molding support a high-grade, fast-growing neuroendocrine carcinoma, but the diagnosis depends on the full pathology evaluation.
What do Ki-67 and the mitotic rate tell me about pancreatic small cell NEC?
Ki-67 is the percentage of tumor cells that are actively multiplying, while the mitotic rate counts dividing cells in a defined area. High-grade neuroendocrine carcinomas generally have a Ki-67 above 20%, and small cell NEC often has a much higher value, but a small biopsy may make the estimate unreliable.
How do doctors distinguish pancreatic small cell NEC from NET G3?
Doctors compare how the cells look, how quickly they are dividing, and their immunostain and molecular patterns. Small cell NEC is poorly differentiated and often shows p53 and Rb abnormalities, whereas NET G3 is well differentiated and may have ATRX, DAXX, or MEN1 abnormalities. Because the treatments differ, expert review and the full clinical context are important.
What do p53, Rb, ATRX, and DAXX results mean on the report?
Strong, diffuse or completely absent p53 staining and loss of Rb support small cell NEC. ATRX and DAXX are usually retained in small cell NEC; loss of either may suggest a well-differentiated NET instead. No single immunostain proves the diagnosis, so results must be interpreted as part of the full panel.
Can a small needle biopsy miss important information about the tumor?
Yes. A small needle biopsy may not represent the entire tumor, so the Ki-67 estimate or detection of mixed components can be limited. Doctors interpret the sample together with immunostains and clinical or radiologic information, and specialist review may help clarify the findings.
Should my pathology slides be reviewed by a neuroendocrine specialist?
A second opinion from a pathologist who specializes in neuroendocrine cancers at a high-volume center is strongly advisable because small cell NEC can be confused with NET G3. Coordinate the review with your treating team so that time-sensitive treatment is not unnecessarily delayed.

Get notified when new evidence is published on pancreatic small cell neuroendocrine carcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (24)
  1. 1

    Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

    Shah MH, Goldner WS, Benson AB, et al.

    Journal of the National Comprehensive Cancer Network : JNCCN 2021; (19(7)):839-868.

    PMID: 34340212
  2. 2

    Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms.

    Eads JR, Halfdanarson TR, Asmis T, et al.

    Endocrine-related cancer 2023; (30(8)).

    PMID: 37184955
  3. 3

    Rb Loss and KRAS Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study.

    Hijioka S, Hosoda W, Matsuo K, et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2017; (23(16)):4625-4632 doi:10.1158/1078-0432.CCR-16-3135.

    PMID: 28455360
  4. 4

    Pancreatic neuroendocrine tumors G3 and pancreatic neuroendocrine carcinomas: Differences in basic biology and treatment.

    Zhang MY, He D, Zhang S

    World journal of gastrointestinal oncology 2020; (12(7)):705-718 doi:10.4251/wjgo.v12.i7.705.

    PMID: 32864039
  5. 5

    Diagnostic and prognostic biomarkers for pancreatic neuroendocrine neoplasms.

    Sonnen AF, Verschuur AVD, Brosens LAA

    Pathologie (Heidelberg, Germany) 2024; (45(Suppl 1)):74-82 doi:10.1007/s00292-024-01393-8.

    PMID: 39556246
  6. 6

    Tri-modal management of primary small cell carcinoma of the pancreas (SCCP): a rare neuroendocrine carcinoma (NEC).

    Elzein S, Bao F, Lin R, et al.

    BMC gastroenterology 2021; (21(1)):340 doi:10.1186/s12876-021-01901-7.

    PMID: 34479480
  7. 7

    The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.

    Basturk O, Yang Z, Tang LH, et al.

    The American journal of surgical pathology 2015; (39(5)):683-90 doi:10.1097/PAS.0000000000000408.

    PMID: 25723112
  8. 8

    Immunohistochemistry in the diagnosis and classification of neuroendocrine neoplasms: what can brown do for you?

    Bellizzi AM

    Human pathology 2020; (96()):8-33 doi:10.1016/j.humpath.2019.12.002.

    PMID: 31857137
  9. 9

    A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.

    Tang LH, Basturk O, Sue JJ, Klimstra DS

    The American journal of surgical pathology 2016; (40(9)):1192-202 doi:10.1097/PAS.0000000000000662.

    PMID: 27259015
  10. 10

    Pancreatic neuroendocrine neoplasms: current state and ongoing controversies on terminology, classification and prognostication.

    Taskin OC, Clarke CN, Erkan M, et al.

    Journal of gastrointestinal oncology 2020; (11(3)):548-558 doi:10.21037/jgo.2020.03.07.

    PMID: 32655934
  11. 11

    Pancreatic neuroendocrine carcinomas reveal a closer relationship to ductal adenocarcinomas than to neuroendocrine tumors G3.

    Konukiewitz B, Jesinghaus M, Steiger K, et al.

    Human pathology 2018; (77()):70-79 doi:10.1016/j.humpath.2018.03.018.

    PMID: 29596894
  12. 12

    Integrated Genomic and Clinicopathologic Approach Distinguishes Pancreatic Grade 3 Neuroendocrine Tumor From Neuroendocrine Carcinoma and Identifies a Subset With Molecular Overlap.

    Umetsu SE, Kakar S, Basturk O, et al.

    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2023; (36(3)):100065 doi:10.1016/j.modpat.2022.100065.

    PMID: 36788102
  13. 13

    Radical intended surgery for highly selected stage IV neuroendocrine neoplasms G3.

    Merola E, Falconi M, Rinke A, et al.

    American journal of surgery 2020; (220(2)):284-289 doi:10.1016/j.amjsurg.2020.03.009.

    PMID: 32209239
  14. 14

    A limited panel of INSM1 and LEF1 immunostains accurately distinguishes between pancreatic neuroendocrine tumor and solid pseudopapillary neoplasm.

    Guo W, Farzaneh T, Lee W, et al.

    Pathology, research and practice 2021; (223()):153462 doi:10.1016/j.prp.2021.153462.

    PMID: 34048981
  15. 15

    Somatostatin receptor expression related to TP53 and RB1 alterations in pancreatic and extrapancreatic neuroendocrine neoplasms with a Ki67-index above 20.

    Konukiewitz B, Schlitter AM, Jesinghaus M, et al.

    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2017; (30(4)):587-598 doi:10.1038/modpathol.2016.217.

    PMID: 28059098
  16. 16

    Performance of Immunohistochemistry to Detect Rb/p53 Alterations in High-Grade Neuroendocrine Neoplasms: Staining Patterns and Comparison with Genetic Testing.

    Chen R, Tihy M, Lacroix L, et al.

    Endocrine pathology 2025; (36(1)):40 doi:10.1007/s12022-025-09885-w.

    PMID: 41160312
  17. 17

    Building a diagnostic scoring system for high-grade neuroendocrine neoplasms of the pancreas.

    Kinowaki Y, Wang C, Fukumura Y, et al.

    American journal of clinical pathology 2026; (165(3)) doi:10.1093/ajcp/aqaf154.

    PMID: 41830603
  18. 18

    Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms.

    Rindi G, Mete O, Uccella S, et al.

    Endocrine pathology 2022; (33(1)):115-154 doi:10.1007/s12022-022-09708-2.

    PMID: 35294740
  19. 19

    Comparison of Three Ki-67 Index Quantification Methods and Clinical Significance in Pancreatic Neuroendocrine Tumors.

    Kroneman TN, Voss JS, Lohse CM, et al.

    Endocrine pathology 2015; (26(3)):255-62 doi:10.1007/s12022-015-9379-2.

    PMID: 26072124
  20. 20

    Pancreatic Neuroendocrine Tumors: From Benchside to Surgical Treatment.

    Conzo G, Mongardini FM, Paolicelli M, et al.

    Medicina (Kaunas, Lithuania) 2026; (62(3)) doi:10.3390/medicina62030479.

    PMID: 41901560
  21. 21

    Immunohistochemical analysis of OTP and NKX6.1 in neuroendocrine tumors of the lung and pancreas.

    Yoxtheimer LM, Heymann JJ, Cohen C, et al.

    Diagnostic cytopathology 2018; (46(12)):1010-1014 doi:10.1002/dc.24088.

    PMID: 30284410
  22. 22

    Mixed pancreatic ductal adenocarcinoma and well-differentiated neuroendocrine tumor: A case report.

    Zhao X, Bocker Edmonston T, Miick R, Joneja U

    World journal of gastrointestinal oncology 2024; (16(12)):4738-4745 doi:10.4251/wjgo.v16.i12.4738.

    PMID: 39678795
  23. 23

    Two Cases of Mixed Neuroendocrine Non-neuroendcrine Cell Neoplasms (MiNENs) of the Pancreas with Notable Molecular Pathological Features.

    Saito S, Takayama Y, Tanaka M, et al.

    Internal medicine (Tokyo, Japan) 2025; (64(23)):3372-3379 doi:10.2169/internalmedicine.5083-24.

    PMID: 40467501
  24. 24

    Fine-Needle Aspiration-Based Grading of Pancreatic Neuroendocrine Neoplasms Using Ki-67: Is Accurate WHO Grading Possible on Cytologic Material?

    Weiss VL, Kiernan C, Wright J, et al.

    Journal of the American Society of Cytopathology 2018; (7(3)):154-459 doi:10.1016/j.jasc.2018.02.001.

    PMID: 30038894

This page is for informational purposes only and does not constitute medical advice or replace review of your pathology report by your treating team. A pathologist experienced in neuroendocrine cancers can help interpret how your specific findings affect care.

Guide contents pancreatic small cell neuroendocrine carcinoma
Research & Literature
02 Symptoms & Warning Signs of Pancreatic SC-NEC 04 Staging & Imaging for Pancreatic SC-NEC